S&P Equity Research downgrades Boston Scientific (NYSE: BSX) from Hold to Sell. Price target dropped from $18 to $13.
This article: 102 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE